Israeli company Alcobra Ltd., which develops treatments for Attention Deficit Hyperactive Disorder (ADHD), has filed a draft prospectus with the American SEC. The Israeli company plans to hold an IPO on Nasdaq at a company value of $100 million, and hopes to raise $15-20 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments